Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

5 Stocks Financial Advisors Are Looking To Buy This Week

All three main indexes appreciated last week as investors maintained a bullish sentiment following positive news in the last several weeks. The Dow Jones Industrial Average inched higher by 0.33%, while the S&P 500 and NASDAQ Composite posted gains of 0.50% and 0.68%, respectively.

Nothing major happened during the holiday week, with the stock market riding the momentum from the positive outcome of the US-China trade deal and Brexit resolution, which removed a lot of uncertainties.

The geopolitical tensions between US and China have eased and it’s already showing in some of the data that was revealed last week. The imports of soybeans from the US surged to 2.56 million tons n November from 1.147 million tons in October following Beijing issuing waivers that allowed importers to forgo tariffs. At the same time, the exports of rare earth magnets to the US from China declined by 21.2% on the back of reduced demand for stockpiling.

On the other hand, the trade relations between the US and the EU might be in the spotlight for the following months. The Italian Parliament adopted a new tax on tech giants effective January 1, joining France, which has recently passed a similar law and the UK, which announced plans to introduce a digital tax at the beginning of December.

Amid a lack of major developments and tepid but steady growth of the stock market, Financial Advisors focused mainly on the tech behemoths, data from TrackStar, InvestingChannel’s official newsletter capturing and analyzing the trends of Financial Advisors, showed. Three tickers that were most searched by Financial Advisors last week were Apple Inc. (NASDAQ: AAPL), Tesla Inc. (NASDAQ: TSLA), and Amazon.com, Inc. (NASDAQ: AMZN).

Tesla

Apple last Monday got a nod of approval from Wedbush, which raised the price target on the stock to $350 from $325, projecting high demand for the new 5G iPhone that is expected in 2020. Tesla last week confirmed several loans from Chinese banks of up to $1.29 billion that will help the company build its plant in Shanghai. The carmaker also announced last week that it will start delivering the first 15 units of Model 3 sedans to company employees on December 30. Amazon was in the spotlight last week amid positive holiday shopping season data. Mastercard said eCommerce sales surged by 18.8% on the year. Amazon itself said that it recorded a record number of Prime users and more than 5.0 million new customers started their Prime trials or memberships in just one week.

On the fourth and fourth and fifth spot in TrackStar’s list we saw AT&T Inc. (NYSE: T) and Visa Inc. (NYSE: V), followed by Intra-Cellular Therapies Inc (NASDAQ: ITCI), a biotech company focused on development of therapies for the central nervous system disorders, whose stock surged by 170% last week.

The main development behind the jump of Intra-Cellular Therapies’ share price is the FDA approval of Caplyta (lumateperone), a drug for the treatment of schizophrenia in adults. The regulator greenlighted the drug despite previous mixed results in trials. In 2016, the drug failed to meet its primary end point and earlier this year, the FDA cancelled an advisory committee meeting regarding Caplyta citing the need to review more information.

Caplyta acts by targeting serotonin, dopamin, and glutamate neurotransmitters in the brain. It also has fewer side-effects compared to existing therapies, such as metabolic disorder that may result in weight-gain, diabetes, high blood pressure and high cholesterol.

The company expects the drug to be available in pharmacies by the end of March 2020. In the meantime, analysts jumped in to provide their view and upgrade the stock. Among them, Canaccord raised the price target to $65 from $29 with a ‘Buy’ rating, citing the potential for lumateperone in the treatment of other disorders (the drug is in late-stage development for other indications).

Disclosure: None. This article is first published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.